Keros Therapeutics, Inc. announced that it presented additional data from its two ongoing Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes ("MDS") and one in patients with myelofibrosis ("MF"), at the 65th American Society of Hematology ("ASH") Annual Meeting and Exposition, held in person in San Diego and virtually from December 9 through 12, 2023. In addition, Keros presented preclinical data showing that a research form of KER-050 promoted hematopoiesis in an animal model of MF, as well as preclinical data evaluating the treatment effect of activin receptor-like kinase 2 inhibition in a mouse model of iron-refractory iron deficiency anemia. Clinical Presentations: Durable Clinical Benefit with KER-050 treatment: Findings From an Ongoing Phase 2 Study in Participants with Lower-Risk MDS; This ongoing, open-label, two-part, Phase 2 clinical trial is evaluating KER-050 in patients with very low-,low-, or intermediate-risk MDS; Modulation of TGF-b Superfamily Signaling by KER-050 administered with or without Ruxolitinib in patients with MF who have anemia and were either currently on, failed, or ineligible for ruxolitinib at baseline.

Safety data are presented for all patients that received at least one dose of KER-050 in Part 1 (n=41) as of September 14, 2023.